[{"orgOrder":0,"company":"Eyestem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Eyestem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Inapplicable"},{"orgOrder":0,"company":"Eyestem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eyecyte-RPE","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eyestem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Inapplicable"},{"orgOrder":0,"company":"Eyestem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelium Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyestem \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eyestem \/ Inapplicable"},{"orgOrder":0,"company":"Eyestem","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"Eyecyte-RPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Eyestem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Undisclosed"}]